19m agoInvesting.com Analyst RatingsBEARISH 42Analyst
Stifel maintains Syndax stock rating after trial failure
Stifel maintains Syndax stock rating after trial failure
Why Is SYNDAX PHARMACEUTICA (SNDX) Stock Down Today?
By the Top Tier Newswire AI Desk · reviewed against 15 wire stories
SYNDAX PHARMACEUTICA (SNDX) is down -17.28% in the latest session. Our newswire has captured 15 stories on SNDX across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 35/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for SNDX publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
SNDX by the numbers
Last: $13.69Session: -17.28%7 sessions: -10.93%Coverage: 15 stories / 7 sourcesAI sentiment: 35/100 (bearish)
The headlines behind the move
1h agoThe FlyBEARISH 42Analyst
Syndax valuation unchanged after trial miss, says H.C. Wainwright
1h agoThe FlyBULLISH 64Analyst
Syndax selloff brings attractive entry point, says Citi
2h agoInvesting.com MarketsBEARISH 38General
Why is Syndax Pharmaceuticals stock sliding today?
Why is Syndax Pharmaceuticals stock sliding today?
3h agoMarketChameleonBEARISH 34Earnings
Syndax halts axatilimab IPF plans after MAXPIRe misses FVC decline endpoint October 13, 2026
Syndax said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet the primary endpoint measuring annualized FVC decline, and the company does not plan further IPF development. The company emphasized axatilimab was well tolerated with no new safety signals and said the results do not affect ongoing cGVHD trials, with additional readouts expected later this year and in early 2028.
4h agoThe FlyBEARISH 34Analyst
Syndax price target lowered to $23 from $26 at BofA
16h agoStocktwits NewsBEARISH 22Earnings
SNDX Stock Slumps 16% After-Hours — What’s Driving The Selloff?
Syndax said on Monday that its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis.
18h agoSeeking AlphaBEARISH 14Earnings
Syndax plummets as IPF asset axatilimab fails in phase 2 trial
Syndax (SNDX) plunges after hours as axatilimab fails Phase 2 idiopathic pulmonary fibrosis endpoint.
18h agoThe FlyBEARISH 22Earnings
Syndax says Phase 2 idiopathic pulmonary fibrosis study misses endpoint
18h agoThe FlyBEARISH 22Earnings
Syndax sinks 15% to $14 after idiopathic pulmonary fibrosis miss
Frequently asked questions
Why is SNDX stock down today?
SYNDAX PHARMACEUTICA (SNDX) is down -17.28% in the latest session. Our newswire has captured 15 stories on SNDX across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 35/100). The most recent driver: "Stifel maintains Syndax stock rating after trial failure" (Investing.com Analyst Ratings).
Is SNDX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of SNDX coverage reads 35/100 over 15 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is FRMI up today (+20.92%)
- Why is CIFR down today (-14.31%)
- Why is FUN down today (-14.18%)
- Why is EFXT up today (+13.66%)
- Why is PS down today (-12.71%)
- Why is CHRN down today (-11.07%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on SNDX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.